CN113747892A - 2,2,2-三氟乙酸1-(2,4-二甲基苯基)-2-[(3-甲氧基苯基)亚甲基]酰肼多晶型物及其制备方法 - Google Patents

2,2,2-三氟乙酸1-(2,4-二甲基苯基)-2-[(3-甲氧基苯基)亚甲基]酰肼多晶型物及其制备方法 Download PDF

Info

Publication number
CN113747892A
CN113747892A CN201980025349.1A CN201980025349A CN113747892A CN 113747892 A CN113747892 A CN 113747892A CN 201980025349 A CN201980025349 A CN 201980025349A CN 113747892 A CN113747892 A CN 113747892A
Authority
CN
China
Prior art keywords
solvent
hydrazide
dimethylphenyl
trifluoroacetic acid
methoxyphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980025349.1A
Other languages
English (en)
Chinese (zh)
Inventor
B·基多恩
W·A·詹兹
吴虹桥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abraxar Pharmaceuticals
Original Assignee
Abraxar Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxar Pharmaceuticals filed Critical Abraxar Pharmaceuticals
Publication of CN113747892A publication Critical patent/CN113747892A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/72—Hydrazones
    • C07C251/86—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to carbon atoms of six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C249/00—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C249/16—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of hydrazones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980025349.1A 2018-02-21 2019-02-20 2,2,2-三氟乙酸1-(2,4-二甲基苯基)-2-[(3-甲氧基苯基)亚甲基]酰肼多晶型物及其制备方法 Pending CN113747892A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862633441P 2018-02-21 2018-02-21
US62/633,441 2018-02-21
PCT/US2019/018835 WO2019164997A1 (en) 2018-02-21 2019-02-20 2,2,2-trifluoroacetic acid 1-(2,4-dimethylphenyl)-2-[(3-methoxyphenyl) methylene] hydrazide polymorphs and method of making the same

Publications (1)

Publication Number Publication Date
CN113747892A true CN113747892A (zh) 2021-12-03

Family

ID=67686904

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980025349.1A Pending CN113747892A (zh) 2018-02-21 2019-02-20 2,2,2-三氟乙酸1-(2,4-二甲基苯基)-2-[(3-甲氧基苯基)亚甲基]酰肼多晶型物及其制备方法

Country Status (6)

Country Link
US (2) US10968167B2 (https=)
EP (1) EP3755316A4 (https=)
JP (2) JP2021525275A (https=)
CN (1) CN113747892A (https=)
CA (1) CA3091782A1 (https=)
WO (1) WO2019164997A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021525275A (ja) * 2018-02-21 2021-09-24 オニール, マイケルO’NEIL, Michael ２，２，２−トリフルオロ酢酸１−（２，４−ジメチルフェニル）−２−［（３−メトキシフェニル）メチレン］ ヒドラジド多形体およびその製造方法
WO2021222438A1 (en) * 2020-04-28 2021-11-04 Abrexa Pharmaceuticals, Inc. Compounds for prevention and treatment of post-intensive care cognitive dysfunction and cognitive dysfunction resulting from respiratory distress

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105801496A (zh) * 2014-12-31 2016-07-27 广州喜鹊医药有限公司 三氟乙酰肼类化合物及其制备方法和在制药中的应用
WO2017015660A1 (en) * 2015-07-23 2017-01-26 Salk Institute For Biological Studies Prevention and treatment of aging and neurodegenerative diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8779002B2 (en) 2007-10-15 2014-07-15 Salk Institute For Biological Studies Methods for treating a variety of diseases and conditions, and compounds useful therefor
JP2021525275A (ja) * 2018-02-21 2021-09-24 オニール, マイケルO’NEIL, Michael ２，２，２−トリフルオロ酢酸１−（２，４−ジメチルフェニル）−２−［（３−メトキシフェニル）メチレン］ ヒドラジド多形体およびその製造方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105801496A (zh) * 2014-12-31 2016-07-27 广州喜鹊医药有限公司 三氟乙酰肼类化合物及其制备方法和在制药中的应用
WO2017015660A1 (en) * 2015-07-23 2017-01-26 Salk Institute For Biological Studies Prevention and treatment of aging and neurodegenerative diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MARGUERITE PRIOR 等: "The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer’s disease mice", 《ALZHEIMER’S RESEARCH & THERAPY》, vol. 5, no. 25, pages 6 *
QI CHEN 等: "A Novel Neurotrophic Drug for Cognitive Enhancement and Alzheimer’s Disease", 《PLOS ONE》, vol. 6, no. 12, pages 15 - 16 *

Also Published As

Publication number Publication date
EP3755316A1 (en) 2020-12-30
JP2021525275A (ja) 2021-09-24
CA3091782A1 (en) 2019-08-29
US11584711B2 (en) 2023-02-21
US20210139416A1 (en) 2021-05-13
WO2019164997A1 (en) 2019-08-29
US10968167B2 (en) 2021-04-06
JP2024038090A (ja) 2024-03-19
US20200399205A1 (en) 2020-12-24
EP3755316A4 (en) 2022-05-25

Similar Documents

Publication Publication Date Title
Garnier et al. Dehydration mechanism and crystallisation behaviour of lactose
Pan et al. Solution-mediated polymorphic transformation of CL-20: An approach to prepare purified form ε particles
EA022756B1 (ru) Кристаллические формы элтромбопага и их применение
JP2024038090A (ja) ２，２，２－トリフルオロ酢酸１－（２，４－ジメチルフェニル）－２－［（３－メトキシフェニル）メチレン］ ヒドラジド多形体およびその製造方法
KR20140108222A (ko) 결정질 형태의 신속한 식별 및 제조를 위한 방법
CN114105969A (zh) Btrx-335140的晶型及其制备方法
HK40065391A (en) 2,2,2-trifluoroacetic acid 1-(2,4-dimethylphenyl)-2-[(3-methoxyphenyl) methylene] hydrazide polymorphs and method of making the same
Nugrahani et al. Theophylline-Na-sacharrine single crystal isolation for its structure determination
US11434204B2 (en) Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide
CA3251157A1 (en) CRYSTALLINE FORMS OF DURLOBACTAM
Li The interactions between pyrazinamide and urea derivatives and their role in the stabilization of the gamma form of pyrazinamide
CN115768753B (zh) 一种gaba抑制剂的晶型及其制备方法
CN116120380B (zh) 葡萄糖胺衍生物的晶型、制备方法及用途
WO2025180349A1 (zh) 化合物的固体及其制备方法和用途
Veverka et al. Crystal habit modifications of imatinib mesylate under various precipitation conditions
JP7201263B2 (ja) Ｃｙｃｌｉｃ－ｄｉ－ＡＭＰナトリウム塩結晶
RU2792728C2 (ru) СПОСОБ ПОЛУЧЕНИЯ ПОЛИМОРФНОЙ ФОРМЫ 3-[5-АМИНО-4-(3-ЦИАНОБЕНЗОИЛ)ПИРАЗОЛ-1-ил]-N-ЦИКЛОПРОПИЛ-4-МЕТИЛБЕНЗАМИДА
RU2765719C2 (ru) Способ получения полиморфной формы 3-[5-амино-4-(3-цианобензоил)пиразол-1-ил]-n-циклопропил-4-метилбензамида
WO2026026772A1 (zh) 氧杂螺环类衍生物的富马酸盐晶型及其制备方法和应用
Karpinska Crystal Growth Using Low Temperature Gradient Sublimation in Vacuo
CN120208778A (zh) 一种替拉曲考晶型及其制备方法
CN114380746A (zh) 依伐卡托新晶型和其制备方法
CN114539339A (zh) 瑞德西韦草酸盐及其制备方法
CN115746004A (zh) 一种阿普唑仑一水合物晶型及其制备方法
KR20080008223A (ko) 결정 구조를 가지는 벤즈옥사진 화합물 및 그 제조 방법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40065391

Country of ref document: HK

CB03 Change of inventor or designer information

Inventor after: M. O'Neill

Inventor after: B. Kidon

Inventor after: W. A. jenz

Inventor after: Wu Hongqiao

Inventor before: B. Kidon

Inventor before: W. A. jenz

Inventor before: Wu Hongqiao

CB03 Change of inventor or designer information